News & Events
Insight Genetics, Inc. today announced the launch of its proprietary Insight TNBCtype™, a new test for categorizing triple negative breast cancer (TNBC) tumors into distinct molecular subtypes through its wholly owned CLIA- and CAP-accredited lab, Insight Molecular Labs. Insight TNBCtype™, the first and only CLIA-validated assay for TNBC molecular subtyping, will enable prospective clinical trials with pharmaceutical, biotechnology, and academic medical institutions and advance targeted therapies for TNBC patients, addressing a significant unmet need in oncology today. The test will be featured in posters presented at the 2018 San Antonio Breast Cancer Symposium from December 4-8, 2018, in San Antonio, Texas.
2015 was an exciting year for Insight Genetics with the formation of new partnerships, continued collaboration with existing partners, expansion of our leadership team, the launch of a CLIA-validated assay for non-small cell lung cancer (NSCLC), presentation of new research findings on triple negative breast cancer (TNBC), and new funding to continue the advancement of the company’s TNBC and NSCLC programs. We look forward to an eventful 2016 as we continue to clinically validate and commercialize our breast and lung cancer assays, adapt these assays for compatibility with liquid biopsies and broader, multi-biomarker panels, expand collaborations with key academic institutions and commercial partners, and extend our services to the pharmaceutical industry.
Insight Genetics, Inc. today announced that Ronald (Ronnie) Andrews Jr., former president of the Genetic Science Division of Thermo Fisher Scientific, has been named to the company’s Board of Directors. Andrews also joined the company’s base of private investors, in a round of $3 Million growth capital that will allow Insight Genetics to expand and expedite its triple negative breast cancer and non-small cell lung cancer programs. The minimum of $3 million has been closed, with a maximum of $5 million targeted.
Insight Genetics, Inc. today announced the launch of its Insight RET Screen™, a Clinical Laboratory Improvement Amendments (CLIA)-validated assay available through Insight Molecular Labs, that detects oncogenic RET (Rearranged during Transfection) expression in non-small cell lung cancer (NSCLC) patients.
Insight Genetics to Present New Data on Subtyping Ovarian Cancer at 2015 American Society of Clinical Oncology Annual Meeting
Insight Genetics will present new data on classifying distinct molecular subtypes of serous ovarian cancer at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.